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Abstract
BACKGROUND: Caveolin-1 is a protein that displays promotive versus preventive roles in cancer progression accord-
ing to circumstances. Temozolomide (TMZ) is the standard chemotherapeutic to treat glioma patients. The present
work aims to characterize TMZ-inducedeffects on caveolin-1 expression in gliomacells.METHODS:Humanastroglioma
(U373 and T98G) and oligodendroglioma (Hs683) cell lines were used in vitro as well as in vivo orthotopic xenografts
(Hs683 andU373) into the brains of immunocompromisedmice. In vitro TMZ-induced effects on protein expression and
cellular localization were determined by Western blot analysis and on the actin cytoskeleton organization by means of
immunofluorescence approaches. In vivo TMZ-induced effects in caveolin-1 expression in human glioma xenografts
were monitored by means of immunohistochemistry. RESULTS: TMZ modified caveolin-1 expression and localization
in vitro and in vivo after an administration schedule that slightly, if at all, impaired cell growth characteristics in vitro.
Caveolin-1 by itself (at a 100-ng/ml concentration) was able to significantly reduce invasiveness (Boyden chambers) of
the three human glioma cell lines. The TMZ-inducedmodification in caveolin-1 expression in flotation/raft compartments
was paralleled by altered Cyr61 and β1 integrin expression, two elements that have already been reported to collab-
orate with caveolin-1 in regulating glioma cell biology, and all these features led to profound reorganization of the actin
cytoskeleton. An experimental Src kinase inhibitor, AZD0530, almost completely antagonized the TMZ-induced mod-
ulation in caveolin-1 expression.CONCLUSION: TMZmodifies caveolin-1 expression in vitro and in vivo in glioma cells,
a feature that directly affects glioma cell migration properties.
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Introduction
The combination of temozolomide (TMZ) with radiotherapy has
been shown to improve survival in glioblastoma (GBM) patients after
surgical resection [1,2]. However, the prognosis associated with GBM
patients remains dismal because i) GBMs cannot be completely re-
moved surgically because of the highly infiltrative nature of these
tumors into the brain parenchyma [1,3] and ii) GBM cells defend
themselves against TMZ during chronic treatments, with the emer-
gence of TMZ-resistant tumors observed at both the experimental
[4] and the clinical [1,2] levels.
The therapeutic benefits contributed by TMZ relates to the fact that
it induces double-strand DNA breaks through generation of methyl-
guanosine [5] concomitantly with sustained autophagy-related pro-
cesses [6,7], all these features ending with apoptosis in GBM cells [8].
TMZ also displays antiangiogenic effects [9]. In contrast, as mentioned
above, TMZ treatment of GBMs can lead to the emergence of TMZ-
resistant tumors. Fisher et al. [10] showed that treatment of human
malignant glioma cells with TMZ activate stress mechanisms that
include up-regulation of angiogenesis-inducing proteins, notably
hypoxia-inducible factor-1α and vascular endothelial growth factor.
We recently demonstrated that TMZ activates galectin-1 (a hypoxia-
regulated protein [11]) expression in malignant glioma cells, a process
that leads to marked proangiogenic effects [12] and the activation of
chemoresistance [13]. The fact of decreasing galectin-1 expression in
experimental malignant gliomas [12,13] and melanomas [14] leads in
turn to increased therapeutic benefits contributed by TMZ.
Numerous hypoxia-regulated proteins are implicated in glioma
biology [15,16] among which caveolin-1 [17], and we were therefore
wondering whether TMZ could modify caveolin-1 expression and/or
cellular localization in GBM cells.
Caveolin-1 is a 21- to 24-kDa scaffold protein and an essential con-
stituent of caveolae, which are flask-shaped invaginations of the plasma
membrane [18]. In caveolae, caveolin-1 directly interacts with several
signaling molecules, including growth factor receptors (e.g., the epider-
mal growth factor receptors [EGFRs]), kinases (including Src), G pro-
teins, and adhesion molecules [19,20]. Caveolin-1 contributes to the
regulation of multiple cancer-associated processes, including cellular
transformation, tumor growth, cell migration and metastasis, cell death
and survival, multiple drug resistance, and angiogenesis [21–23]. How-
ever, both cancer growth-enhancing and growth-inhibiting effects
have been reported for caveolin-1 under different conditions [21–
23]. Caveolin-1 is expressed in normal and malignant glial cells [24–
27] as well as in brain blood vessels [28].
The present work thus aims to i) investigate as whether TMZ is able
to modify caveolin-1 expression and/or cellular localization in glioma
cells, ii) characterize caveolin-1–mediated effects on glioma cell inva-
sion, and iii) identify some signaling elements by which TMZmodifies
caveolin-1 expression in detergent-insoluble floating complexes of
glioma cells.
We used three GBM models. The U373 and T98G models are
of astrocytic origin [29,30]. U373 GBM cells display resistance to
proapoptotic stimuli [30,31] but actual sensitivity to sustained pro-
autophagic stimuli, leading to massive cell death [32]. The Hs683
GBM model is of oligodendroglial origin [29,33] and displays sensi-
tivity to proapoptotic drugs [30,31]. Hs683 GBM cells contain only
one Notch2 gene copy per diploid genome as do oligodendrogliomas,
whereas U373 GBM cells contain two copies as do astrogliomas
[34]. The HS683 model might correspond to the few GBMs display-
ing an oligodendroglial origin [35] and/or component [36]. These
three models markedly and diffusely invade the brain parenchyma
when orthotopically grafted into the brains of immunocompromised
mice [4,9,12,30,37].
Materials and Methods
Cell Cultures and Compounds
Hs683 (ATCC code HTB-138), U373 (ATCC code HTB-17),
and T98G (ATCC code CRL-1690) human GBM cell lines were
obtained from the American Type Culture Collection (ATCC, Ma-
nassas, VA) and maintained in our laboratory, as detailed previously
[9,12,13,32,33,38,39].
TMZ was obtained from Schering Plough (Brussels, Belgium).
Caveolin-1 recombinant protein purified on glutathione sepharose 4
Fast Flow was obtained from Abnova (Taipei, Taiwan), Nycodenz
(5-(N -2,3-dihydroxypropylacetamido)-2,4,6-tri-iodo-N -N ′-bis(2,3
dihydroxypropyl) isophthalamide), a nonionic iodinated gradient me-
dium was purchased from Gentaur (Brussels, Belgium), and the EGFR
kinase inhibitor (erlotinib) and Src tyrosine kinase inhibitor (AZD0530)
were obtained from Selleck Chemicals Co (Shanghai, China).
Protein Extraction for Raft Resident Caveolin-1
Caveolin-1 is a part of caveolae that are Triton-insoluble complexes
and are difficult to solubilize using conventional detergents found in
typical lysis buffers. Therefore, flotation of detergent-insoluble proteins
was performed as described by Naslavsky et al. [40].
Briefly, in all experiments, confluent cells growing in three 75-mm
dishes were pelleted and lysed with 750 μl of lysis buffer (1% of
TX-100 in TNE (150 mM NaCl, 25 mM Tris-HCl, and 5 mM
EDTA, pH 7.5)) on ice for 30 minutes. Lysates were spun at low speed
(3000 rpm, 4°C, 5 minutes) to generate a postnuclear supernatant. All
subsequent steps were performed on ice. Lysates were adjusted to
35% Nycodenz by adding an equal volume of ice-cold 70% Nycodenz
dissolved in TNE. One-and-a-half milliliters of the samples was loaded
at the bottom of 4-ml tubes (BeckmanCoulter, Analis, Suarlee, Belgium).
An 8% to 25% Nycodenz linear step gradient in TNE was then over-
laid above the lysate (350 μl each of 25%, 22.5%, 20%, 18%, 15%,
12%, and 8% Nycodenz). The tubes were spun at 55,000 rpm for
4 hours at 4°C in a Beckman Optima LE-80K with a SW 60 Ti rotor
(Beckman Coulter). Twelve 330-μl fractions were collected from the
bottom of the tube.
Protein Expression Measurements
Western blot analyses were performed to measure protein expres-
sion, as detailed previously [9,12,13,38,39]. The primary antibody in-
cubation step was omitted as a negative control experiment. Integrity
and quantity of the extracts were assessed by tubulin immunoblot
analysis. Proteins were detected by Western blot analysis using the fol-
lowing primary antibodies: anti–caveolin-1 (1:250 dilution; BD Trans-
duction Laboratories, Erembodegem, Belgium), antitubulin (1:3000
dilution; Abcam, Cambridge, UK), anti-Cyr61 (1:1000 dilution;
Abcam, Cambridge, UK), and anti–β1 integrin (1:500 dilution; BD
Transduction Laboratories). Secondary antibodies were purchased from
Pierce (PerbioScience, Erembodegem, Belgium). Western blots were
developed using the Pierce SuperSignal Chemiluminescence System.
Cytology
The effect of TMZ (100 μM) on actin cytoskeleton organization
of GBM cells was investigated using fluorescent probes, as detailed
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elsewhere [39,41]. The green fluorochrome Alexa Fluor 488–conjugated
phallacidin (Molecular Probes, Inc, Invitrogen, Merelbeke, Belgium)
was used to label fibrillary actin, whereas the red fluorochrome Fluor
594–conjugated DNAseI (Molecular Probes, Inc) was used to label
globular actin.
Invasion Assay
Invasive features of T98G, U373, and Hs683 GBM cells were
assessed in vitro using the Boyden transwell invasion system (BD
BioCoat Matrigel invasion chambers; BD Biosciences Discovery
Labware, Bedford, MA), as detailed elsewhere [33]. We studied the
effects of caveolin-1 on malignant glioma cell migration when ap-
plied to the top as opposed to the bottom of the Boyden chambers.
Immunohistochemical Procedures for Human
Glioma Xenografts
We used histologic slides for caveolin-1 immunohistochemical stain-
ing in Hs683 and U373 GBM xenografts from a previous in vivo ex-
periment, in which we demonstrated TMZ-induced antiangiogenic
effects and improvements in survival [9]. In this previous experiment,
immunocompromised mice bearing orthotopic Hs683 or U373 xeno-
grafts were treated (or left untreated as control) three times a week
(Monday, Wednesday, and Friday) for three and five consecutive weeks,
respectively, with TMZ (40 mg/kg, intravenously) [9].
The mouse brains were fixed in 4% buffered formaldehyde,
routinely processed, and paraffin-embedded. Three-micrometer sec-
tions were prepared and routinely stained with hematoxylin and
eosin. Two additional sections, collected on SuperFrost Plus Slides,
were used for immunohistochemical analysis. Caveolin-1 immuno-
reactivity was studied in all cases, and the immunohistochemical
reaction with the anti–caveolin-1 antibody (rabbit polyclonal anti-
body, diluted 1:350; Santa Cruz Biotechnology, Santa Cruz, CA) was
performed in an automated immunostainer (Ventana BenchMark
Auto-Stainer; Ventana Medical Systems, Tucson, AZ).
Results
Temozolomide Modulates Raft Resident Caveolin-1 Expression
in Human GBM Cell Lines In Vitro
We previously determined the 50% reduction in in vitro growth
(IC50) concentrations for TMZ on after 3 days of glioma cell culture
with the drug, and we obtained 118 ± 3 μM for U373, 634 ± 23 μM
for T98G, and 719 ± 12 μM for Hs683 GBM cells [9]. In the current
experiment, U373, T98G, and Hs683 GBM cells were chronically
treated in vitro with 100 μM TMZ, which was added to the culture
medium each day for 7 hours (after which fresh medium replaced
the medium with drugs for 17 hours) for five consecutive days. Protein
analyses were performed at 3, 5, and 7 days after the fifth TMZ
addition to the GBM culture medium (Figures 1 and 2). We previously
Figure 1. Temozolomide modulates raft resident caveolin-1 expression in vitro and increases caveolin-1 expression in vivo in experimental
GBMs. (A) Western blot analysis of the expression of raft resident caveolin-1 in the different flotation fractions (F4-F12) obtained from T98G
GBM cells left untreated (CT) or treated with 100 μM TMZ for 7 h/d for five consecutive days. Raft resident caveolin-1 expression was
measured on the third day (day 3) after the end of the TMZ treatment. (B) Caveolin-1 immunoreactivity in Hs683 GBM tumors implanted
into brains of immunodeficient mice and treated (Bb and Bc) or not treated (Ba) with TMZ (40 mg/kg per os, three times per week for three
consecutive weeks, with immunohistochemical analyses performed 1 week after the end of the treatment). Caveolin-1 expression was
absent from the Hs683 tumor (T) left untreated (Ba), in which only the vessels (Vs) were immunoreactive for caveolin-1. Caveolin-1 expres-
sion was marked in Hs683 tumors (T) after TMZ treatment (Bb). Caveolin-1 expression in the tumor bulk (T) was associated with accumu-
lation of caveolin-1 in the extracellular matrix around the invasive part of the tumor (black arrows in Bc). The normal brain (NB) expressed
weak levels of caveolin-1 (Bc).
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showed that 5 × 100 μM TMZ treatment (with observation 7 days
after the fifth TMZ administration) did not impair T98G cell popu-
lation growth, slightly impaired Hs683 cell population growth, and
moderately impaired U373 cell population growth [9]. Thus, the
in vitro 5 × 100 μM treatment adopted here for three distinct human
GBM cell lines slightly, if at all, impaired cell growth characteristics.
Raft resident caveolin-1 was expressed in flotation fractions 5 to
12 of the T98G GBM cell line with the largest expression in fractions
5 to 8 (Figure 1A). TMZ treatment, 3 days after the fifth in vitro
administration into the culture medium, changed the expression and
therefore the localization of raft resident caveolin-1 into the different
flotation compartments: caveolin-1 disappeared from fraction 5, de-
creased in fractions 6 to 8, and increased in fractions 9 to 11 with
TMZ treatment (Figure 1A). We obtained similar results with the
two other GBM cell lines (data not shown). Raft resident caveolin-1
was not expressed in fractions 1 to 4 of the three GBM cell lines (data
not shown).
By contrast, using a classic extraction method, the three GBM cell
lines did not express soluble caveolin-1 under control conditions,
whereas they displayed increased intracellular soluble caveolin-1 expres-
sion 3 to 5 days after the fifth in vitro administration of TMZ into
the culture medium (Figure 4A).
Temozolomide Increases Caveolin-1 Expression in Human
GBM Xenografts In Vivo
Chronic TMZ treatment modified raft resident caveolin-1 expres-
sion in vitro in T98G GBM cells (Figure 1A) and in Hs683 and
U373 (data not shown) and in vivo in Hs683 (Figure 1B) and in
U373 (data not shown) GBM xenografts. Immunohistochemical
analyses further revealed that the highest TMZ-induced increases in
caveolin-1 expression was observed in the extracellular matrix, par-
ticularly around the invasive areas (the black arrows in Figure 1Bc) of
the tumor (T in Figure 1Bc) compared with normal brain parenchyma
(NB in Figure 1Bc).
Temozolomide Decreases β1 Integrin Expression and
Modulates Cyr61 Signaling and Actin Cytoskeleton
Polymerization in Human GBM Cell Lines In Vitro
Caveolin-1 is part of the signaling pathways controlling integrin
function and expression, as previously demonstrated for α5β1 integrins
Figure 2. Temozolomide decreases β1 integrin and modulates Cyr61 and actin cytoskeleton organization in GBM cell lines. (A) Western
blot analysis of the expression of β1 integrin in U373, T98G, and Hs683 GBM cells left untreated (CT) or treated with 100 μM TMZ for 7 h/d
for five consecutive days. The β1 integrin expression was measured on the third (day 3), fifth (day 5), and seventh (day 7) days after the end
of the TMZ treatment. (B) Western blot analyses of the expression of Cyr61 in U373, T98G, and Hs683 GBM cell lines left untreated (CT)
or treated with 100 μM TMZ using a treatment schedule identical to that described above for β1 integrin. (C) Fluorescence microscopic
visualization of the actin cytoskeleton (red fluorescence shows globular (nonpolymerized) actin and green fluorescence shows fibrillary
(polymerized) actin) under control conditions (CT) and 3 (TMZ D3) and 5 (TMZ D5) days after termination of TMZ (100 μM) treatment in
U373 (Ca) and Hs683 (Cb) glioma cells according to a treatment schedule identical to that described above for β1 integrin.
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[42]. Caveolin-1 has also been identified as a component in cysteine-
rich 61 (Cyr61) integrin signaling [43]. Cyr61 is a matricellular protein,
and expression of this protein is known to correlate with poor prognosis
in GBM patients [44]. TMZ-induced effects on α5β1 integrin and
Cyr61 expression were investigated in Hs683, U373, and T98G GBM
cells in vitro (Figure 2). We again adopted a regimen of daily in vitro
TMZ (100 μM) treatment for 7 h/d over five consecutive days.
TMZ did not modify α5 integrin expression patterns in these three
GBM cell lines (data not shown). In contrast, we found that TMZ
significantly decreased expression levels of β1 integrin in the GBM cell
lines of astroglial origin (i.e., U373 and T98G) 5 or 7 days after the fifth
in vitro administration of TMZ (Figure 2A). In addition, β1 integrin
expression levels progressively increased over time in these two GBM
models of astroglial origin (Figure 2A). In contrast, β1 integrin ex-
pression levels progressively decreased over time in the Hs683 GBM
model of oligodendroglial origin, and TMZ failed to further decrease
levels over control (Figure 2A). We previously demonstrated marked
differences in β integrin expression levels between astrogliomas and
oligodendrogliomas, and between U373 and T98G versus Hs683
GBM cells [29]. Whereas U373 and T98G GBM cells display marked
β1 expression, as do astrogliomas [29,45], Hs683 GBM cells display
high levels of β4 integrin, as do oligodendrogliomas [29,45]. The dif-
ferences in β integrin expression between U373 and T98G GBM
cells with an astroglioma origin versusHs683 GBM cells with an oligo-
dendroglioma origin [29] could explain, at least partly, why TMZ did
not induce similar patterns of β1 integrin expression in U373, T98G,
and Hs683 GBM cells (Figure 2A).
The same features have been observed with respect to Cyr61. In-
deed, chronic in vitro TMZ (100 μM) treatment for 7 h/d for five con-
secutive days significantly decreased expression levels of the secreted
form of Cyr61 in U373 and T98G GBM cell lines of astrocytic origin,
whereas this treatment had no effect or even slightly increased expres-
sion of the Cyr61 secreted form in the Hs683 GBM cell line of oligo-
dendroglial origin (Figure 2B). The reasons for the differences in the
full-length Cyr61 observed with TMZ treatment are not yet under-
stood for the moment (Figure 2B).
Malignant glioma adhesion depends on various integrins [29,45–
47], and modifications in integrin signaling and/or expression can
modify actin cytoskeleton organization [48]. Figure 2C reveals that
TMZ treatment significantly depolymerized actin stress fibers not
only in U373 and T98G cells (data not shown) but also in Hs683
GBM cells. This effect was sustained even 5 days after termination
of TMZ treatment (Figure 2Ca). The finding that TMZ depolymer-
ized the actin cytoskeleton in Hs683 oligodendroglioma cells but did
not change β1 integrin expression may indicate the involvement of
other β integrins [29,45–47], expression of which may be modified by
TMZ treatment.
Extracellular Caveolin-1 Significantly Decreases U373,
T98G, and Hs683 GBM Cell Invasiveness In Vitro
Caveolin-1 is secreted by androgen-insensitive prostate cancer cells
and is detected in the serum of patients with prostate cancer [49,50].
The highest reported serum level of caveolin-1 was approximately
100 ng/ml [49]. We therefore used 10 and 100 ng/ml caveolin-1 to
investigate whether caveolin-1 can modify invasiveness of glioma cells
cultured in Boyden chambers in vitro. As shown in Figure 3, 100 ng/ml
caveolin-1 applied to the top of the Boyden chambers significantly
decreased the invasiveness levels in the two GBM models of astrocytic
origin (i.e., U373 and T98G) but not in the Hs683 GBM model of
oligodendroglial origin. In contrast, caveolin-1 added to the bottom
of the Boyden chamber reduced invasiveness in the three models, sug-
gesting that caveolin-1 exerted repulsive, or nonpermissive, effects on
glioma cell migration and invasion. Lower concentrations (10 ng/ml)
of caveolin-1 did not modify glioma cell invasiveness (data not shown).
Altogether, these data suggest that part of the therapeutic benefits
Figure 3. Extracellular caveolin-1 decreases GBM cell line in-
vasion. Invasion was evaluated using Matrigel Boyden chambers.
The number of invasive cells was counted in 10 fields per cham-
ber (the chamber surface includes 30 fields), and the experiment
was conducted in triplicate. The mean of the 10 values was used
to calculate the percentage of invasive cells in the population
seeded, and the control invasion rate shown on each graph
was reported to be 100%. The effects of 100 ng/ml recombinant
caveolin-1 were examined both when the protein was added in the
upper (“Top”; promigratory or antimigratory factor) or the lower
(“Bottom”; chemoattractant vs chemorepulsive factor) compart-
ments of the chamber. Results are expressed as mean of the
triplicate ± SE.
96 TMZ Modifies Caveolin-1 Expression in Gliomas Bruyère et al. Translational Oncology Vol. 4, No. 2, 2011
contributed by TMZ treatment in GBM patients could relate to TMZ-
induced modification in caveolin-1 expression, a feature that in turn
seems to lower GBM cell invasiveness.
Temozolomide-Induced Caveolin-1 Modulation in GBM Cells
Is at Least Partly Mediated through Src Signaling
Caveolin-1 actively interacts with Src and EGFR [19,20], and sev-
eral Src and EGFR inhibitors are currently assayed in clinical trials as
potential treatments for recurrent GBM patients (clinicaltrial.gov) [51].
We therefore investigated the effects of inhibitors of EGFR kinase
(erlotinib) and Src (AZD0530) on TMZ-induced intracellular solu-
ble caveolin-1 expression in Hs683 GBM cells. Figure 4 shows that
AZD0530 prevented TMZ-induced soluble caveolin-1 expression but
did not change basal levels of soluble caveolin-1 in Hs683 GBM cells.
In contrast, erlotinib increased soluble caveolin-1 expression to a simi-
lar degree as TMZ in these Hs683 GBM cells (Figure 4). These data
suggest that Src could be a signaling element for TMZ when increas-
ing intracellular soluble caveolin-1 expression in GBM cells. In con-
trast, EGFR seems to negatively regulate soluble caveolin-1 expression
in GBM cells and its inhibition leads to increased soluble caveolin-1
expression, a feature that becomes additive to the TMZ-induced
effects on soluble caveolin-1 expression in these Hs683 GBM cells
(Figure 4). Reconciling the data from Figure 3 with those from Fig-
ure 4 suggests that a treatment combining an anti-EGFR compound
with TMZ would reinforce an increase in soluble caveolin-1 expres-
sion (Figure 4), which in turn would decrease GBM cell invasiveness
(Figure 3).
Discussion
GBM cells develop TMZ resistance during long-term treatment,
and this resistance is partly mediated by O(6)-methylguanine-DNA
methyltransferase (MGMT) [5,52]. The MGMT promoter methyla-
tion status [53], but not anti-MGMT immunohistochemistry [54],
can be used to predict responses to TMZ treatment in GBM pa-
tients. Identification of additional biomarkers that would predict
distinct clinical responses at the single patient level within MGMT-
positive and -negative groups of GBM patients will help in tailoring
a drug regimen to the specific biochemistry and particular vulner-
abilities of each patient’s tumor, thereby increasing effectiveness and
avoiding unnecessary toxicities [32,51]. We already suggested such
a potential role for galectin-1 [55], and the current study investigated
such a potential role for caveolin-1. Data from the present study show
that TMZ-treated GBM cells differently express raft resident and solu-
ble caveolin-1 compared with untreated GBM cells.
Evidence for a role of caveolin-1 in cancer biology remains controver-
sial [56–61]. Even within the specific group of gliomas, immunohisto-
chemical caveolin-1 expression varies among glioma subgroups [25,26].
Caveolin-1 is upregulated in cancer cells facing adverse events. Spe-
cifically, caveolin-1 induction in tumor cells and tumor endothelial
cells after radiation was previously shown to be responsible for the ac-
quisition of a radio-resistant phenotype [62,63]. Conversely, HDAC
inhibitors, proteasome inhibitors, and vascular endothelial growth fac-
tor receptor inhibitors, which are in clinical trials for GBM [51], were
shown to reduce caveolin-1 levels. Moreover, Palozza et al. [64] re-
cently demonstrated that β-carotene acts as a growth-inhibitory agent
in caveolin-1–positive human colon and prostate cancer cells but not
Figure 4. The TMZ-induced caveolin-1 modulation is Src-dependent in Hs683 GBM cells. (A) Western blot analysis of the expression
of soluble caveolin-1 in U373, T98G, and Hs683 GBM cells left untreated (CT) or treated with 100 μM TMZ for 7 h/d for five consecu-
tive days. Soluble caveolin-1 expression was measured on the third (day 3) and fifth (day 5) days after the end of the TMZ treatment. (B)
Western blot analyses of soluble caveolin-1 expression in Hs683 glioma cells treated with TMZ (100 μM) four times per week (day 1-4)
for 7 h/d, the EGFR inhibitor (10 μM) (erlotinib; day 1), the Src inhibitor AZD0530 (10 μM) (day 1), and combination of the inhibitors and
TMZ (+TMZ) compared with control untreated cells (Ct). Soluble caveolin-1 expression was measured on day 5.
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in caveolin-1–negative cells. This finding suggests that modifications
in caveolin-1 expression in glioma cells treated with TMZ could also
modify the response of cells to future treatments.
The fact remains that as long as cancer cell biology is taken into
account, caveolin-1–related roles seem to be tightly dependent on
the cancer cell type may be because various cancer cell types express
various activated signaling pathways. Data from the present study
clearly evidence opposite roles for EGFR and Src on TMZ-induced
modulation in caveolin-1 expression (Figure 4).
Accumulating experimental evidences indicate that caveolin-1 regu-
lates signal transduction–associated proteins in caveolae [19,20,22].
For example, caveolin-1 modifies expression levels of Src, EGFR,
endothelial nitric oxide synthase, G protein α and subunits, and
H-Ras [65]. Several groups have provided rationale for interaction be-
tween caveolin-1 and β1 integrin [62,66,67]. Caveolin-1 promotes
Fyn-dependent shc phosphorylation and MAPK activation in response
to integrin ligation through association with β1 integrins and the
Src-related kinase Fyn [66]. This would strengthen the rationale to
explore these pathways in gliomas. Conversely, Src and other kinases
phosphorylate caveolin-1 on Tyr14 in response to various stimuli, and
this phosphorylation is crucial for caveolin-1 functions [48]. The
interaction at Tyr14 contributes to modifications in the actin cyto-
skeleton organization [48,68].
By manipulating the levels of caveolin-1 in a GBM cell line (U87MG),
Martin et al. [42] showed that reduced levels of caveolin-1 shifted
cells toward a more aggressive phenotype, whereas forced expression
of caveolin-1 slowed proliferation, clonogenicity and invasion. The
current data perfectly fit in with those data reported by Martin et al.
[42] because we show here that caveolin-1 reduces GBM cell invasion
(Figure 3).
In addition, it is already well documented that GBM microenviron-
ment directly affects GBM cell biology [15,16,69]. Our current data
suggest that GBMmicroenvironment may also be a major determinant
of caveolin-1–mediated roles in cancer cell biology according to the fact
that TMZ-mediated increased caveolin-1 expression GBM xenografts
mainly occur in the glioma microenvironment (Figure 1Bc).
In conclusion, TMZ modified caveolin-1 expression in vitro and
in vivo in human GBM models of astrocytic versus oligodendroglial
origin, and this effect seemed to be mediated partly through activa-
tion of Src signaling but not of EGFR signaling. In contrast, blocking
EGFR also leads to increases in soluble caveolin-1 expression in GBM
cells. TMZ-induced modification in caveolin-1 expression in GBM
cells was paralleled by the decrease in β1 integrin expression and
disorganization of the actin cytoskeleton. Caveolin-1 decreases GBM
cell invasion.
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